Renaissance Technologies Portfolio: Top 10 Stock Picks

2. United Therapeutics Corporation (NASDAQ:UTHR)

Stake Value as of Q4 2024: $737,221,073

United Therapeutics Corporation (NASDAQ:UTHR) is an American biotechnology company developing novel medications for chronic and life-threatening diseases. It is among the top stock picks from the Renaissance Technologies portfolio, with the hedge fund having investments of over $737 million in the company.

On December 17, 2024, United Therapeutics Corporation (NASDAQ:UTHR) announced the world’s first successful UKidney transplant into a living person. The transplant, authorized by the FDA, was the fourth xenotransplant performed on humans using the company’s xeno organs. Before this, there were two successful UHeart transplants in 2022 and 2023, and one UThymoKidney transplant earlier in 2024.

In February this year, the FDA cleared United Therapeutics Corporation (NASDAQ:UTHR)’s Investigational New Drug application for a clinical study of its investigational UKidney, with the first xenotransplant in the trial expected to happen around mid-2025. An estimated 557,000 patients in the United States are on dialysis from kidney diseases. The company believes xenotransplants can be a therapeutic alternative to dialysis.

United Therapeutics Corporation (NASDAQ:UTHR) has also recently announced full enrollment of the TETON 1 study to evaluate the use of Tyvaso inhalation solution to treat idiopathic pulmonary fibrosis, which is a significant step in potentially delivering a transformative treatment option for patients living with the disease.

The company’s innovative research and development, and advancements in ongoing trials have led to a bullish sentiment around the stock. Wall Street analysts have a consensus Buy rating for United Therapeutics Corporation (NASDAQ:UTHR) with an average share price upside potential of 5%.